BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Director Amy E. Mckee Sells 8,600 Shares

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Director Amy E. Mckee sold 8,600 shares of the stock in a transaction on Monday, June 24th. The shares were sold at an average price of $6.32, for a total value of $54,352.00. Following the transaction, the director now directly owns 27,831 shares in the company, valued at $175,891.92. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

BioCryst Pharmaceuticals Stock Performance

Shares of BioCryst Pharmaceuticals stock opened at $6.08 on Wednesday. BioCryst Pharmaceuticals, Inc. has a one year low of $4.03 and a one year high of $7.95. The stock’s fifty day moving average is $5.68 and its 200 day moving average is $5.62. The stock has a market cap of $1.25 billion, a P/E ratio of -5.68 and a beta of 1.87.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its earnings results on Monday, May 6th. The biotechnology company reported ($0.17) EPS for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.06. The company had revenue of $92.80 million during the quarter, compared to the consensus estimate of $85.62 million. During the same period in the prior year, the business posted ($0.28) earnings per share. BioCryst Pharmaceuticals’s revenue for the quarter was up 34.9% compared to the same quarter last year. Analysts predict that BioCryst Pharmaceuticals, Inc. will post -0.66 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the company. JMP Securities increased their price target on BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the company a “market outperform” rating in a report on Tuesday, May 7th. HC Wainwright reissued a “buy” rating and set a $30.00 price target on shares of BioCryst Pharmaceuticals in a report on Tuesday, May 7th. Finally, Needham & Company LLC reissued a “buy” rating and set a $12.00 price target on shares of BioCryst Pharmaceuticals in a report on Tuesday, May 7th. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $14.00.

Institutional Investors Weigh In On BioCryst Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. raised its holdings in BioCryst Pharmaceuticals by 15.4% during the fourth quarter. Vanguard Group Inc. now owns 17,763,720 shares of the biotechnology company’s stock valued at $106,405,000 after acquiring an additional 2,371,401 shares during the period. Avoro Capital Advisors LLC raised its holdings in BioCryst Pharmaceuticals by 13.0% during the fourth quarter. Avoro Capital Advisors LLC now owns 13,050,000 shares of the biotechnology company’s stock valued at $78,170,000 after acquiring an additional 1,500,000 shares during the period. Kynam Capital Management LP raised its holdings in BioCryst Pharmaceuticals by 41.9% during the first quarter. Kynam Capital Management LP now owns 6,527,491 shares of the biotechnology company’s stock valued at $33,160,000 after acquiring an additional 1,927,491 shares during the period. Braidwell LP raised its holdings in BioCryst Pharmaceuticals by 6.6% during the fourth quarter. Braidwell LP now owns 5,718,477 shares of the biotechnology company’s stock valued at $34,254,000 after acquiring an additional 355,497 shares during the period. Finally, Deerfield Management Company L.P. Series C raised its holdings in BioCryst Pharmaceuticals by 148.6% during the third quarter. Deerfield Management Company L.P. Series C now owns 3,286,000 shares of the biotechnology company’s stock valued at $23,265,000 after acquiring an additional 1,964,000 shares during the period. 85.88% of the stock is owned by institutional investors.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.